Charles River Labs (CRL) Gets a Hold Rating from Barclays

Barclays analyst Jack Meehan maintained a Hold rating on Charles River Labs (CRLResearch Report) today and set a price target of $154.00. The company’s shares closed last Monday at $125.12.

According to TipRanks.com, Meehan is a 4-star analyst with an average return of 2.3% and a 56.6% success rate. Meehan covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, PRA Health Sciences, and Myriad Genetics.

Charles River Labs has an analyst consensus of Strong Buy, with a price target consensus of $180.64.

See today’s analyst top recommended stocks >>

The company has a one-year high of $179.38 and a one-year low of $95.58. Currently, Charles River Labs has an average volume of 447.7K.

Based on the recent corporate insider activity of 67 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CRL in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support. The Research Models & Services segment comprises of the production and sale of research models, and also offers services designed to support its client’s use of research models in screening non-clinical drug candidates. The Discovery & Safety Assessment segment offers discovery and safety assessment services, both regulated and non-regulated, in which it include both in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. The Manufacturing Support segment provides endotoxin and microbial detection, avian vaccine and biologics testing solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.